Federico Nasroulah
Global Executive Director, Clinical Lead, Oncology Clinical Development Daiichi Sankyo
Dr. Federico Nasroulah is a medical oncologist and clinical developer with almost 2 decades of experience in the pharmaceutical industry and a decade in academia. Currently he is the Global Clinical Lead for Datopotomab Deruxtecan (Datroway®), an ADC targeting TROP2.
Over the years, Federico acquired experience in multiple approaches for cancer treatment, from antiangiogenic monoclonal antibodies to small molecules, immunotherapies, and ADCs. He led his teams to multiple successful global regulatory approvals including Ramucirumab in colorectal cancer, Nivolumab in bladder cancer, and Datroway in HR+/Her2- metastatic breast cancer.
Seminars
Wednesday 5th November 2025
Exploring the Clinical Profile & Journey of Datroway from TROPION-Breast Trials & Assessing Future Directions in Solid Tumor Indications
9:00 am
- Detailing clinical data from TROPION-Breast01 trial with US and Japanese approval in previously metastatic HR positive, HER2 negative breast cancer
- Exploring fresh insights from TROPION-Breast02 in triple negative breast cancer
- Looking ahead to TROPION-Breast 03, 04, and 05 trials and highlighting other investigations of Datroway in solid tumorsÂ
